Table 1. Targeted Therapies for Metastatic (or locally advanced)
Breast Cancer
Company
Product
Generic Name Type Indications Dose
Genentech
Tecentriq
atezolizumab
Immune
checkpoint
inhibitor
Triple-negative
breast cancer
expressing PD-L1
840 mg every 2 weeks,
1200 mg every 3 weeks, or
1680 mg every 4 weeks prior
to paclitaxel 100 mg/m
2
on
days 1, 8, and 15 for each 28
day cycle
Merck
Keytruda
pembrolizumab
Immune
checkpoint
inhibitor
Triple-negative
breast cancer
expressing PD-L1
200 mg every 3 weeks or
400 mg every 6 weeks with
chemotherapy
Gilead
Trodelvy
sacituzumab
govitecan
Trop-2-directed
antibody and
topoisomerase
inhibitor
conjugate
mTNBC patients
who have received
two or more
prior systemic
therapies, at least
one of them for
metastatic disease
10 mg/kg IV once weekly on
Days 1 and 8 of continuous
21-day treatment
AstraZeneca /
Merck
Lynparza
olaparib
PARP inhibitor 2nd line for
HER2-negative
metastatic breast
cancer
300 mg taken orally twice
daily
Pfizer
Talzenna
talazoparib
PARP inhibitor Deleterious
or suspected
deleterious
germline
BRCA-mutated
(gBRCAm)
HER2-negative
breast cancer
1 mg taken orally once daily
Eisai
Halaven
eribulin mesylate
Microtubule
inhibitor for
single agent
chemotherapy
3rd line for
metastatic breast
cancer
1.4 mg/m IV over 2–5
minutes on Days 1 and 8 of a
21 day cycle
R-Pharm US
Ixempra
ixabepilone
Microtubule
inhibitor for
single agent
chemotherapy or
with capecitabine
2nd line for the
treatment of
metastatic or
locally advanced
breast cancer
40 mg/m IV over 3 hours
every 3 weeks
